<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48673">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02018328</url>
  </required_header>
  <id_info>
    <org_study_id>rmc137511</org_study_id>
    <nct_id>NCT02018328</nct_id>
  </id_info>
  <brief_title>The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection</brief_title>
  <acronym>CurHP</acronym>
  <official_title>The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gingold Belfer Rachel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <authority>Israel: Clalit Health Services</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Aims

        -  H.pylori is a common human pathogen by which almost 50% of the world population is
           infected. According to the accepted guidelines, once H.pylori infection has been
           diagnosed,first line therapy with three drugs should be given. The triple treatment
           includes proton-pump-inhibitor-clarithromycin-amoxicillin but its eradication rate is
           only 70-80%.

        -  Curcumin has many beneficial merits and it was also been demonstrated to be efficient
           in inhibition of H.pylori infection, in vitro.Therefore we aim to investigate whether
           addition of Curcumin to the standard triple therapy will increase the eradication rate
           of H.pylori infection.

      Methods

        -  150 consecutive patients that will undergo esophagogastroscopy in our Gastroenterology
           department and will be positive for H.pylori according to urease test and then by
           gastric biopsy, will be included. The patients will be randomized to two different
           treatments, according to binomial distribution. 75 patients will be treated with the
           standard triple therapy for 10 days and the other 75, will be treated for 10 days, with
           triple therapy combined with Curcumin that will be given three times a day.

        -  During the treatment the patients will complete an adverse effect's questionnaires. 6
           weeks after the completion of the treatment the patients will undergo urea breath test
           to confirm eradication. Patients will be asked to avoid antibiotics, bismuth compounds
           or proton-pump-inhibitor until the second urea-breath-test.

        -  We will compare the eradication rate and the adverse effects between the two groups by
           using SPSS
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Urea breath test</measure>
    <time_frame>6 weeks after the completion of the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Positivity for Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>Triple therapy, helicobacter pylori</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>triple therapy+curcumin helicobacter pylori</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin will be added to the regular triple therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <arm_group_label>triple therapy+curcumin helicobacter pylori</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  positivity for Helicobacter pylori by urease test and gastric biopsy

        Exclusion Criteria:

          -  prior treatment for H. pylori

          -  allergy to penicillin

          -  gastric outlet obstruction

          -  pregnancy or breast feeding

          -  inability to understand the informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachel Gingold belfer, MD</last_name>
    <email>RahelGB@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Gingold Belfer, MD</last_name>
      <phone>974-54-2405895</phone>
      <email>RahelGB@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rachel Ginold Belfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Gingold Belfer, MD</last_name>
      <phone>974-54-2405895</phone>
      <email>RahelGB@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rachel Gingold Belfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Malfertheiner P, Megraud F. Management of helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut.61 (5):646-64.2012 Hatcher H , Planalp R . Curcumin: from ancient medicine to cuurent clinical trials. Cell Mol Life Sci. 65(11):1631-52. 2008. Forty-Ludwig A, Neumann M. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori - infected epithelial cells. Biochem Biophys Res Commun. 316(4): 1065-72. 2004</citation>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Gingold Belfer Rachel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
